|
Schirdewan博士的引述的參考文獻: : F$ [7 a) S5 U7 v3 G" C
8 |( u) I; d% d$ Q: l" {: A7 O0 F8 nCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. , _6 e$ Z- C; V
) O8 U) m, u$ L$ ~" D/ L' R+ f7 lDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
5 Z2 ?( z! I$ @9 A, h% p0 g2 b/ M' k' J1 _/ m& w" J
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. % s2 o2 l9 ]7 B2 J3 G& _' o$ J* s9 i
' ]2 V& p$ k$ N- [1 w! Q
關於BIOTRONIK SE & Co. KG# Q' X* n6 O/ l
0 Q. {# n# ?- G! G% ^8 N
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|